FindTrial
Sign In

Efficiency of two drugs in allergic rhinitis

Evaluation of oral fexofenadine versus intranasal azelastine in patients with allergic rhinitis: A randomized control trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/030042
Enrollment
144
Registered
2020-12-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified

Interventions

Intervention1: Azelastine: Intranasal spray, 2puff both nostril B.D for 4weeks Control Intervention1: Fexofenadine: Tablet, 120mg O.D for 4weeks

Sponsors

Rohilkhand medical college and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients willing to participate in this study. All patients including both the gender in between the age of 18 to 60 years7. All patients with Allergic Rhinitis.

Exclusion criteria

Exclusion criteria: Female patients during Pregnancy and Lactation. Patients with Hypertensive Heart Disease, Diabetes mellitus, Thyroid Dysfunction. Patients with nasal mass.

Design outcomes

Primary

MeasureTime frame
To reduce symptom score of patient (SFAR)Timepoint: 0,2,4,8 weeks—

Secondary

MeasureTime frame
To improve the quality of life of the patientsTimepoint: 0,2,4,8 weeks—

Countries

India

Contacts

Public ContactDr Abhinav Srivastava

Rohilkhand medical college and hospital

drabhinavsrivastava7@gmail.com9794956306

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026